2月26日 - ** 制药商Madrigal Pharmaceuticals MDGL.O股价上涨13.8%至352.3美元
** 该公司报告称， (link)，其脂肪肝药物Rezdiffra的第四季度销售额为1.033亿美元，超过分析师估计的7195万美元（根据LSEG汇编的数据）。
** 一项评估 Rezdiffra 的后期研究的两年期数据显示，它有助于显著减轻代谢功能障碍相关性脂肪性肝炎患者的肝脏僵硬程度(MASH)
** 称51%的试验入组患者的肝僵化程度降低了25%或更多 -MDGL
** 肝脏僵硬度的显著降低与终末期肝病进展的减少有关 -MDGL
** MASH 是一种严重的疾病，会导致肝脏脂肪过度堆积，引起器官炎症和纤维化或瘢痕形成。
** 股价在过去 12 个月中上涨了 33
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.